PXL770 + Placebo Oral Capsule
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Fatty Liver
Conditions
Nonalcoholic Fatty Liver
Trial Timeline
Mar 29, 2019 → Aug 10, 2020
NCT ID
NCT03763877About PXL770 + Placebo Oral Capsule
PXL770 + Placebo Oral Capsule is a phase 2 stage product being developed by Poxel for Nonalcoholic Fatty Liver. The current trial status is completed. This product is registered under clinical trial identifier NCT03763877. Target conditions include Nonalcoholic Fatty Liver.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03763877 | Phase 2 | Completed |
Competing Products
20 competing products in Nonalcoholic Fatty Liver